DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on May 12, 2008; DOI: 10.1124/dmd.108.020511


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.020511v1
36/8/1553    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakamoto, S.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakamoto, S.
Right arrow Articles by Sugiyama, Y.


Received for publication January 17, 2008.
Revised May 2, 2008.
Accepted for publication May 8, 2008.

Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of S-8921 glucuronide, a pharmacologically active metabolite of S-8921

Shingo Sakamoto 1, Hiroyuki Kusuhara 2, Kazutoshi Horie 3, Kohji Takahashi 3, Takahiko Baba 3, Jun Ishizaki 3, Yuichi Sugiyama 2*

1 SHIONOGI. & CO.,LTD. 2 The University of Tokyo 3 Shionogi & Co., Ltd.

* Address correspondence to: E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp

Abstract

The glucuronide conjugate of S-8921 (S-8921G) is a 6,000-fold more potent inhibitor of an ileal apical sodium-dependent bile acid transporter (SLC10A2) than S-8921, and is responsible for the hypocholesterolemic effect of S-8921 in rats. Since S-8921G is formed in the intestine and liver, the present study investigated the transporters involved in the secretion of S-8921G which govern its exposure to the target site and, thereby, play an important role in its pharmacological action. OATP1B1 and OATP1B3-expressing cells exhibited saturable accumulation of S-8921G with Km values (µM) of 1.9. The uptake of [14C]S-8921G by human cryopreserved hepatocytes was saturable, and sodium-independent. Comparison of protein expression between the cDNA transfectants and hepatocytes suggests that the contribution of OATP1B1, OATP1B3 and NTCP to the hepatic uptake of S-8921G is 63, 35 and 2.6%, respectively. The basal-to-apical transport of S-8921G was enhanced in MDCK cells expressing both OATP1B1 and MRP2. In Mrp2-deficient mutant rats (EHBR), the biliary excretion clearance based on the plasma concentration was 20% of the normal value, while the pharmacokinetic parameters did not show any significant change in Bcrp-/- mice. Furthermore, the secretion clearance of S-8921G to the mucosal side was also significantly lower in everted jejunum sacs from EHBR (9.18 and 20.8 µL/min/g tissue). These results suggest that MRP2 is responsible for the secretion of S-8921G to the intestinal lumen and bile, and OATP1B1 and -1B3 account for the hepatic uptake. These transporters deliver S-8921G to the target site of its pharmacological action.


Key words: ABC transporters, biliary excretion, drug disposition, drug efflux, drug transport, hepatobiliary transport, MRP, organic anion transport, transporters





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.